NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)

NCI Community Oncology Research Program - Protocol Summary

SWOG S1207 - "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (E3 Breast Cancer Study - Evaluating Everolimus with Endocrine Therapy)"

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.

This summary is not intended to be used in place of the full eligibility & treatment information in the protocol.

Please contact KCCOP for complete protocol information.

Print This Summary

Breast Clinical Trial

NCT NUMBER: 01674140

UPDATED ON 01/30/2019 (17:02:33)


Adj., Stgs I-III, high-risk, ER &/or PgR+, HER2(-); Endocrine therapy + Everolimus/placebo.  DCP-001 Eligible


Treatment Plan     (Supplied Drug:  Everolimus/placebo)



Everolimus / placebo:  10mg, PO, QD (preferably am), x 378 days

Endocrine therapy:  Choice of therapy dependent on menopausal status & patient/physician preference (see §7.2), x >5 yrs


Blood specimens for the BAHO substudy are no longer required as of 10-15-15


  • Histol-confirmed invasive breast carcinoma, ER+ &/or PgR+, HER2(-).  Standard adjuv endocrine therapy must be planned.  ER+ &/or PgR+ by ASCO/CAP guidelines >1% positive nuclear staining.  HER2 by ASCO/CAP guidelines using IHC,ISH or both (if IHC 2+, an eval for gene amplification must be done and not amplified).
  • No mets (Stg IV) breast cancer.  Multifocal, multicentric, synchronous bilat, & prim inflammatory breast cancers are allowed (see protocol definitions).
  • Must be high-risk, by one of following:
    • Completion of adjuvant chemotherapy and pathologically negative lymph nodes, and a tumor measuring ≥ 2 cm in greatest diameter, and an Oncotype DX® Recurrence Score > 25 (completed as standard of care). Patients with micrometastases as the only nodal involvement (pN1mi) are eligible, and will be categorized as node-negative.
    • Completion of adjuvant chemotherapy, and pathologically 1-3 positive lymph nodes, and either an Oncotype DX® Recurrence Score > 25 (screened via S1007 or otherwise) or tumor tissue with pathological Grade III following local practice. If Oncotype DX® is done, then RS must be > 25. If the test is not done, but the patient has Grade III disease then the patient is eligible and Oncotype DX® does not need to be performed.
    • Completion of adjuv chemo & pathologically >4 positive LNs.
    • Completion of neoadjuvant chemotherapy and 1 or more positive nodes pathologically determined prior to or after chemotherapy.
  • Completed breast-conserving surgery or total mastectomy, w/negative margins (no tumor or DCIS at resection line) & appropriate axillary staging.  Additional operative procedures may be done to obtain clear margins.
    • If breast-conserving surgery, must have completed whole breast RT.  Use of regional nodal basin RT at investigator's discretion.
    • If >4 positive LNs, must have completed breast/chest wall & nodal basin RT pre-randomiz.
    • Registered >21 days post-RT completion & recovered <Grade 1 from any RT effects.
  • Must have undergone axillary stating by sentinel node bx or axillary lymph node dissection (ALND). 
    • For patients with 1-3 positive lymph nodes, sentinel node biopsy alone is allowed provided that the patient completed either whole breast or chest wall radiation and the primary tumor is < 5 cm.
    • All pts w/>4 positive LNs must have completed ALND (w/ or w/o prior sentinel node bx).
  • Patients must have completed standard neoadjuvant or adjuvant taxane and/or anthracycline based chemotherapy prior to randomization. Completion of chemotherapy will be determined by the treating oncologist, but should include a minimum of 4 cycles (a cycle of weekly paclitaxel is considered 3 doses). Patients must be registered within 42 weeks after the last dose of chemotherapy. Patients may have started endocrine therapy at any time after the diagnosis of the current breast cancer.
  • No current or planned Trastuzumab.  Concurrent bisphosphonate therapy is allowed.  No prior mTOR inhibitors.  No prior investigational drug w/i 28 days, and no other planned investigational drug for study duration.
  • Within 28 days pre-regist:  ANC >1500/mL; Hgb >9g/dL, platelets >100,000/mL; bili <1.5mg/dL (or <3.0mg/dL if due to Gilbert's Syndrome); SGOT, SGPT, & alk phos each <1.5x IULN; serum creat <IULN; fasting cholesterol <300mg/dl; triglycerides <2.5x IULN (lipid lowering agents allowed to reach these values).
  • Zubrod 0-2.
  • No >Grade III cardiac disease by NYHA criteria, unstable angina pectoris, MI w/i past 6 mos, or serious uncontrolled cardiac arrhythmia.
  • If previously diagnosed w/diabetes, must not have uncontrolled diabetes (Hg A1c >7%) w/i 28 days pre-regist.
  • No organ allograft or other prior immune compromise.  No use of chronic, systemic corticosteroids/other immunosuppressive agents.  Topical or inhaled steroids are allowed.
  • HIV+ pts may be enrolled if baseline CD4 >500 cells/mm3 & not taking anti-retroviral therapy.  Patients with known hepatitis are not eligible unless there is a known negative hepatitis panel. Patients must not have any known uncontrolled underlying pulmonary disease.
  • Able to take PO meds.  No impairment of GI function or GI disease significantly altering the absorption of blinded drug.
  • No immunization w/attenuated live vaccine w/i 7 days pre-regist, or plans to receive such vaccine while on protocol tx.
  • No CYP3A4 inhibitors &/or inducers w/i 14 days pre-regist, or plans to take while on protocol tx.
  • No other prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, or other cancer disease-free >5 yrs.
  • No pregnant or nursing women.  Women/Men of reproductive potential must use effective, non-hormonal contraception.
  • Must be offered participation in the Behavioral & Health Outcomes Study (BAHO).  Pts who have already started endocrine therapy are eligible for the BAHO study.
    • H&P, ht, wt, perf status within 28 days prior to registration
    • BAHO questionnaire
    • CBC/diff/platelets
    • Serum creat
    • Bili
    • Alk phos
    • Fasting cholesterol & triglycerides
    • Tissue for correlative studies & banking (MANDATORY)*
    • Blood for correlative studies & banking (MANDATORY)**
  • Signed informed consent.
  • *      Preferably paraffin block, positive LN block, & negative LN block (punch bx [2nd choice] or 20 slides [3rd choice]) may be substituted. With patient consent, residuals will be banked for future research.

    **     7.5mL whole blood in lavender top EDTA Vacutainer tube & 10mL whole blood in red-top or SST Vacutainer tube.


  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA